273 related articles for article (PubMed ID: 1929250)
1. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.
Swanson RN; Hardy DJ; Shipkowitz NL; Hanson CW; Ramer NC; Fernandes PB; Clement JJ
Antimicrob Agents Chemother; 1991 Jun; 35(6):1108-11. PubMed ID: 1929250
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of nitazoxanide against Clostridium difficile.
McVay CS; Rolfe RD
Antimicrob Agents Chemother; 2000 Sep; 44(9):2254-8. PubMed ID: 10952564
[TBL] [Abstract][Full Text] [Related]
3. Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.
Anton PM; O'Brien M; Kokkotou E; Eisenstein B; Michaelis A; Rothstein D; Paraschos S; Kelly CP; Pothoulakis C
Antimicrob Agents Chemother; 2004 Oct; 48(10):3975-9. PubMed ID: 15388461
[TBL] [Abstract][Full Text] [Related]
4. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
5. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
[TBL] [Abstract][Full Text] [Related]
6. Fidaxomicin: in Clostridium difficile infection.
Duggan ST
Drugs; 2011 Dec; 71(18):2445-56. PubMed ID: 22141387
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
[TBL] [Abstract][Full Text] [Related]
8. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile.
Nagaro KJ; Phillips ST; Cheknis AK; Sambol SP; Zukowski WE; Johnson S; Gerding DN
Antimicrob Agents Chemother; 2013 Nov; 57(11):5266-70. PubMed ID: 23939887
[TBL] [Abstract][Full Text] [Related]
9. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.
Babakhani F; Seddon J; Robert N; Shue YK; Sears P
Antimicrob Agents Chemother; 2010 Jun; 54(6):2674-6. PubMed ID: 20308366
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters.
Fekety R; Silva J; Toshniwal R; Allo M; Armstrong J; Browne R; Ebright J; Rifkin G
Rev Infect Dis; 1979; 1(2):386-97. PubMed ID: 549190
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
[TBL] [Abstract][Full Text] [Related]
12. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activities of fidaxomicin.
Goldstein EJ; Babakhani F; Citron DM
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S143-8. PubMed ID: 22752863
[TBL] [Abstract][Full Text] [Related]
14. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
Babakhani F; Gomez A; Robert N; Sears P
J Med Microbiol; 2011 Aug; 60(Pt 8):1213-1217. PubMed ID: 21349983
[TBL] [Abstract][Full Text] [Related]
15. Fidaxomicin: a review of its use in patients with Clostridium difficile infection.
Scott LJ
Drugs; 2013 Oct; 73(15):1733-47. PubMed ID: 24136090
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.
Mascio CT; Mortin LI; Howland KT; Van Praagh AD; Zhang S; Arya A; Chuong CL; Kang C; Li T; Silverman JA
Antimicrob Agents Chemother; 2012 Oct; 56(10):5023-30. PubMed ID: 22802252
[TBL] [Abstract][Full Text] [Related]
18.
Oka D; Yamaya N; Kuno T; Asakawa Y; Shiragiku T; Chen L; Xue J; Mamuti A; Ye F; Sun J; Ohguro K; Miyamoto H; Uematsu Y; Inagaki K; Cheng JF; Matsumoto M
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495229
[TBL] [Abstract][Full Text] [Related]
19. Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea.
Leahy RG; Serio AW; Wright K; Traczewski MM; Tanaka SK
J Glob Antimicrob Resist; 2022 Sep; 30():96-99. PubMed ID: 35500838
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.
Barbut F; Decré D; Burghoffer B; Lesage D; Delisle F; Lalande V; Delmée M; Avesani V; Sano N; Coudert C; Petit JC
Antimicrob Agents Chemother; 1999 Nov; 43(11):2607-11. PubMed ID: 10543736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
